tldrdailynews.com logo

FDA Advisory Committee Evaluates Sarepta's Gene Therapy for Duchenne Amid Concerns.

1 min read
Source: STAT
FDA Advisory Committee Evaluates Sarepta's Gene Therapy for Duchenne Amid Concerns.
Photo: STAT
TL;DR

The FDA advisory panel will meet on Friday to discuss Sarepta Therapeutics' experimental gene therapy for Duchenne muscular dystrophy. This will be the first hearing for a Duchenne drug from Sarepta since 2016, when the FDA overruled its committee's recommendations and authorized an earlier therapy from the company despite limited evidence, leading to celebrations from families and outcry from senior agency officials.

Topics:businesshealthcare#advisory-panel#duchenne-muscular-dystrophy#fda#gene-therapy#healthcare#sarepta-therapeutics
Share this article
  1. What to know about a pivotal FDA hearing on Sarepta's gene therapy for Duchenne  STAT
  2. 'It's transformational work,' Sarepta working on groundbreaking gene therapies in Columbus  ABC6OnYourSide.com
  3. Ahead Of Sarepta Advisory Committee, FDA Feels Congressional Pressure About Public Participation  Pink Sheet
  4. FDA reviewers had string of concerns about Sarepta's gene therapy for Duchenne, documents show  STAT
  5. Sarepta's Duchenne gene therapy faces FDA advisory committee  STAT

Want the full story? Read the original reporting

Read on STAT